PatientsVille.com Logo

MEMORY IMPAIRMENT and Effexor

PatientsVille

MEMORY IMPAIRMENT Symptoms and Causes

Every day, you have different experiences and you learn new things. Your brain cannot store all of that information, so it has to decide what is worth remembering. Memory is the process of storing and then remembering this information. There are different types of memory. Short-term memory stores information for a few seconds or minutes. Long-term memory stores it for a longer period of time.

Memory doesn't always work perfectly. As you grow older, it may take longer to remember things.

It's normal to forget things once in awhile. We've all forgotten a name, where we put our keys, or if we locked the front door. If you are a senior who forget things more often than others your age, you may have mild cognitive impairment. Forgetting how to use your phone or find your way home may be signs of a more serious problem, such as

  • Alzheimer's disease
  • Other types of dementia
  • Stroke
  • Depression
  • Head injuries
  • Blood clots or tumors in the brain
  • Kidney, liver, or thyroid problems
  • Reactions to certain medicines

If you're worried about your forgetfulness, see your health care provider.

NIH: National Institute on Aging

Check out the latest treatments for MEMORY IMPAIRMENT

MEMORY IMPAIRMENT treatment research studies

Effexor clinical trials, surveys and public health registries


Find Drug Side Effect reports



Effexor Side Effects

Dizziness (758)
Nausea (642)
Anxiety (625)
Depression (552)
Feeling Abnormal (546)
Headache (543)
Suicidal Ideation (501)
Condition Aggravated (471)
Paraesthesia (420)
Insomnia (400)
Malaise (400)
Fatigue (339)
Crying (334)
Hyperhidrosis (312)
Confusional State (308)
Agitation (292)
Tremor (286)
Diarrhoea (284)
Asthenia (279)
Convulsion (276)
Completed Suicide (222)
Hypertension (221)
Fall (219)
Disturbance In Attention (207)
Vomiting (204)
Aggression (201)
Blood Pressure Increased (194)
Anger (193)
Withdrawal Syndrome (183)
Somnolence (180)
Pain (177)
Suicide Attempt (175)
Weight Increased (163)
Abnormal Behaviour (151)
Dyspnoea (150)
Amnesia (150)
Intentional Overdose (136)
Irritability (135)
Abnormal Dreams (123)
Tinnitus (118)
Activities Of Daily Living Impaired (117)
Serotonin Syndrome (115)
Loss Of Consciousness (111)
Panic Attack (111)
Arthralgia (110)
Nightmare (109)
Disorientation (108)
Off Label Use (106)
Overdose (106)
Emotional Disorder (105)

➢ More


Common Meds

Abilify (10132)
Adderall (1304)
Amlodipine (6664)
Amoxicillin (4387)
Benadryl (1568)
Celebrex (12876 )
Celexa (1342)
Cialis (2975)
Cipro (8580)
Citalopram (7792)
Crestor (18839)
Cymbalta (14373)
Doxycycline (1757)
Effexor (7289)
Flexeril (435)
Flomax (2177)
Fluoxetine (4261)
Gabapentin (4593)
Hydrocodone (2469)
Ibuprofen (8222)
Lantus (10968)
Lexapro (3499)
Lipitor (17769)
Lisinopril (8919)
Lyrica (27148)
Medrol (650)
Mirena (41254)
Mobic (957)
Morphine (5356)
Naproxen (538)
Neurontin (6501)
Oxycodone (4438)
Pradaxa (13372)
Prednisone (5926)
Prilosec (2631)
Prozac (1954)
Seroquel (27216)
Simvastatin (8348)
Synthroid (4452)
Tamiflu (5585)
Topamax (3748)
Tramadol (5054)
Trazodone (1458)
Viagra (5394)
Vicodin (1153)
Wellbutrin (6324)
Xanax (2847)
Zocor (5718)
Zoloft(6792)
Zyrtec(1669)

Recent Reviews

10 years on effexor, weight gain of 20 lbs last 5 years when increased to 300mg., no change in cal or exercise, since getting older realized needed fewre calories so tried to reduce like always could wirhWW and exercise, no success, couldn'

Effexor & Pristiq is poison - I would know, I started taking it at 16 yrs old, instead of counselling I was given Effexor by a 'psychiatrist drug dealer' I was never offered counselling. I spent of $25,000 on this medication in my lifetime. D

Effexor raised my blood presure alot ,I had extreme painful headaches,rash that started on my face which was horrible,then spread to my chest,my neck was beat red I itched so badly.I think docotrs need to be more educated on this med before giveing i

Effexor was horrible for me...as soon as I started it I started having panic attacks worse than ever (supposed to help them) scary bad dreams, waking up in a sweat and not knowing who I was, then depression. The first day I expeirenced the panic atta

Ever since i've been prescribed effexor, my systolic bp measurement is high. is there a correlation between the two.

Had effexor yesterday 75 mg not again nusea,blurred vision and today the worst longest headache I have ever had,GP didn't even check my BP before prescription.I am recovering from a fractured skull think I will deal with my depression without drugs

Headaches BAD and very sleepy and increased anxiety

Hi.. I have been on effexor. I stopped 'cold turkey'. I know this is wrong. I have gained 25 pounds in the past year. I have increasingly became more depressed. I can't sleep. I have strong thoughts of wanting to die. I don't want to kill myself, but

I agree, this has been a horrile drug experience for me as well .. Effexor should be OFF the market !!!! 46 yr old female, Baltimore MD USA

I am taking 300mg of effexor and I believe is it causing dysuria. Could this be correct?

As you know, I asked I thought, for the impossible. To refresh you all memory I was very much in love with my best friend (we are both women) well she decided to leave her fianc nine weeks after I ordered your Powerful Love Spell. I am not sure i

since i started novothyral my pulse jumped, and tired,memory problems,my body feels week,unable to do anythyng physical, all in all my life going nowhere since two months ago when i started taking this pill thanks very much a

Have taken hydrea for a year because my spleen had increased in size. I have noticed increased loss of memory and some confusion for the past couple of months. I take 500 mg every other day and 1000 mg every other day.

I am having cramps, muscle pain, memory loss, I have been on Revlmid for about 1 year. Does anybody else my age have this disease, I am only 46 yr woman.

Extreme fatigue, sleeplessness, short term memory and speech difficulties, Edema, weight gain, stumbling, shortness of breath, numbness in both legs, and completely kills ability to achieve orgasm.

<span style='color: #808080;'><b>What do You think about Vision impairment and blindness?</b>

Anon- I would say the weed would cause the MOST memory loss used over time also depending on how strong it is ie, (haze, kush....dro...regs from 60's with seeds) THE STONGER it is the faster the brain cells go! As far as the valium/dia

<strong>Found Celepram effective at the end of the 3rd week. Effectiveness lasted for around 14 days. Following period i experienced continualled short term memory loss, hallucinations of seeing stars, skin irritated rash, shortness of breath &

45 Male on Enbrel 4 + years , My condition is all but gone and I really use no other meds now. Expect a dry cough , Poor night vision ,Memory loss ,and in some cases (345) amniesia. IHAVE noticed a difficulty in learning new&am

8 day ago I had an endoscopy where they used Versed. Since then I have had a horrible time with short term memory. I have had episodes of feeling agressive, angry and verbally hostile and seemed to be 'out of control'.&a

MEMORY IMPAIRMENT Clinical Trials and Studies

Treatments might be new drugs or new combinations of drugs, new surgical procedures or devices, or new ways to use existing treatments. The goal of clinical trials is to determine if a new test or treatment works and is safe. Clinical trials can also look at other aspects of care, such as improving the quality of life for people with chronic illnesses. People participate in clinical trials for a variety of reasons. Healthy volunteers say they participate to help others and to contribute to moving science forward. Participants with an illness or disease also participate to help others, but also to possibly receive the newest treatment and to have the additional care and attention from the clinical trial staff.
Rank Status Study
1 Unknown  Repetitive Transcranial Magnetic Stimulation Compared or Associated With Venlafaxine for Depressive Disorder
Condition: Depression
Interventions: Other: active rTMS and active Venlafaxine;   Other: active rTMS and sham Venlafaxine;   Other: sham rTMS and active Venlafaxine
Outcome Measures: The primary outcome measure is remission;   fMRI;   CGI;   QIDS-C30;   UKU Scale
2 Recruiting Venlafaxine PK Following Bariatric Surgery
Conditions: Roux en Y Gastric Bypass;   Sleeve Gastrectomy
Intervention: Drug: Venlafaxine IR and Venlafaxine XR
Outcome Measures: Venlafaxine Plasma Concentrations/Area-Under-the-Curve (AUC);   Secondary PK Characteristics (Composite)
3 Recruiting Study to Examine the Effect of Gastric Bypass Surgery on Venlafaxine ER Blood Levels
Conditions: Bariatric Surgery;   Gastric Bypass;   Roux-en-Y Gastric Bypass
Intervention: Drug: venlafaxine ER (extended-release) 75 mg
Outcome Measure: Venlafaxine levels pre- and post-gastric bypass
4 Recruiting ADAPT: Addressing Depression and Pain Together
Conditions: Depression;   Back Pain
Interventions: Other: Combination Treatment with Higher-dose venlafaxine + PST-DP;   Drug: Higher-dose venlafaxine and supportive management
Outcome Measures: Depression: Patient Health Questionnaire-9;   Pain: 20-Point Numeric Rating Scale;   Self-Efficacy: Chronic Pain Self-Efficacy Scale
5 Recruiting Quality of Life Study Using Gabapentin Versus Venlafaxine in Treating Hot Flashes in Patients With Prostate Cancer
Condition: Hot Flashes in Men With Prostate Cancer Receiving Androgen Ablation Therapy
Interventions: Drug: Gabapentin;   Drug: Venlafaxine
Outcome Measures: Changes in quality of life;   compare toxicity rates between the gabapentin and venlafaxine treatment groups;   Assess changes in the hot flash scores for the two arms;   Assess changes in quality of life using the Hot flash related Daily Interference Scale (HFRDIS)
6 Recruiting Effectiveness Study to Compare Venlafaxine With Fluoxetine in the Treatment of Postmenopausal Women With Major Depression
Condition: Major Depression
Intervention: Drug: venlafaxine,fluoxetine
Outcome Measures: change of 24-item Hamilton Rating Scale for Depression total score;   the mean change of HAMD-24 subscale score in items 10, 11, 12, 13 (anxiety and somatizations) at endpoint
7 Recruiting Estimate the Efficiency of the Association of an Injection of Ketamine and the Venlafaxine in the Severe Major Depressive Disorder for Six Weeks
Condition: Major Depressive Disorder
Interventions: Drug: ketamine venlafaxine;   Drug: Venlafaxine
Outcome Measure: Depressive state
8 Recruiting The HELP PAIN Trial
Condition: Neck Pain
Intervention: Drug: Venlafaxine
Outcome Measures: Average neck pain;   Chronic neck pain
9 Recruiting Venlafaxine for Depression in Alzheimer's Disease (DIADs-3)
Conditions: Alzheimer's Disease;   Depression
Interventions: Drug: Placebo;   Drug: Venlafaxine
Outcome Measures: 225 mg daily dose of venlafaxine over 12 weeks will produce changes in response on the modified AD Cooperative Study-Clinical Global Impression of Change and the Cornell Scale for Depression in Dementia.;   Examine in a proof of concept, 12-week randomized controlled trial, the safety of venlafaxine at a target dose of 225 mg daily for the treatment of Depression in patients with AD.
10 Not yet recruiting Beta-arrestins and Response to Venlafaxine in Major Depressive Disorder (MDD) (DEPARRESTCLIN)
Conditions: Major Depressive Disorder;   Major Depressive Episode
Intervention: Drug: Venlafaxine extended release
Outcome Measure: Change from baseline in depressive symptoms on the Hamilton Depression Rating Scale-17 items
11 Recruiting Venlafaxine Augmentation in Treatment Resistant Depression
Condition: Depression
Interventions: Drug: Venlafaxine;   Drug: Quetiapine
Outcome Measures: Hamilton Depression Rating Scale (HDRS);   Self reported psychopathology (Beck Depression Inventory [BDI], State-Trait Anxiety Inventory [STAI]);   Cognitive function
12 Unknown  Hippocampal Volume in Young Patients With Major Depression Before and After Combined Antidepressive Therapy
Condition: Depressive Disorder, Major
Interventions: Drug: Mirtazapine;   Drug: Venlafaxine
Outcome Measures: Categorial response to the medication. Categorial response is defined on the basis of CGI Improvement scale and 50% reduction in MADR-S score;   Tolerability of treatment as assessed using the DOTES scale;   Cognitive deficits as judged by the SKT system;   Self assessment of depression and anxiety using Beck's Depression/Anxiety Inventory (BDI/BAI);   Changes is blood levels of homocysteine, folate, vit B12, P11
13 Unknown  Pharmacogenomics Studies of Antidepressants
Conditions: Major Depressive Disorder;   Antidepressive Agents;   Pharmacogenetics;   Venlafaxine;   Fluoxetine
Interventions: Drug: Venlafaxine;   Drug: Fluoxetine
Outcome Measures: Hamilton Depression Rating Scale (HDRS);   C-reactive Protein and IL-6;   fasting blood glucose, lipid profiles
14 Recruiting International Study to Predict Optimised Treatment - in Depression
Condition: Major Depressive Disorder
Interventions: Drug: Escitalopram;   Drug: Sertraline;   Drug: Venlafaxine XR
Outcome Measures: To determine whether the genetic-brain-cognition function markers (or combination of markers) 'normalise' with acute drug treatment in MDD;   To determine whether markers of acute treatment prediction are also predictive of functional outcome over 6-12 months.
15 Recruiting A Study of Sustained-Release Desvenlafaxine Hydrochloride for the Treatment of Major Depressive Disorder
Condition: Major Depressive Disorder
Interventions: Drug: Sustained-Release Desvenlafaxine Hydrochloride;   Drug: Sustained-Release Venlafaxine Hydrochloride
Outcome Measures: Change From Baseline on the Hamilton Rating Scale for Depression, 17-item Total Score (HAM-D17);   Change From Baseline on the Clinical Global Impression Scale;   Change From Baseline in Clinical Global Impression-Improvement (CGI-I) Scale;   Change From Baseline in Sheehan Disability Scale (SDS) Total Score at Week 10;   Change From Baseline in Adjusted Mean on Montgomery-Asberg Depression Rating Scale (MADRS);   Change From Baseline on the Visual Analogue Scale-Pain Intensity (VAS-PI);   Number of Participants in Remission Based on the HAM-D17 at Week 10
16 Unknown  Treatment of Mild to Moderate Depression Symptoms in Patients With Spinal Cord Injury
Condition: Spinal Cord Injury
Interventions: Drug: Venlafaxine HCI;   Other: Placebo
Outcome Measures: The Patient Health Questionnaire-9 (PHQ-9);   The Beck Scale for Suicide Ideation (BSS);   16 item Quick Inventory of Depressive Symptomatology (QIDS- SR16);   The SCI Pain Instrument (SCIPI);   The Adherence and Side Effects Checklist;   CAGE & Drug Use;   Generalized Anxiety Disorder-7 (GAD-7);   The Perceived Stress Scale (PSS);   Life Experiences Survey - Disability (LES-D);   The Received Social Support and Social Undermining Scale (RSS/SU);   Measure of the Quality of the Environment;   The Perceived Handicap Questionnaire (PHQ);   Craig Handicap Assessment and Reporting Form - Short Form (CHART-SF);   The SF-12 Health Status Questionnaire - 12
17 Unknown  Electroencephalography (EEG) Signal Processing
Condition: Major Depressive Disorder
Interventions: Drug: Venlafaxine;   Drug: bupropion;   Drug: escitalopram;   Other: Psychotherapy;   Drug: Duloxetine
Outcome Measure: Machine learning
18 Recruiting Efficacy of Repetitive Transcranial Magnetic Stimulation in the Prevention of Relapse of Depression
Condition: Depression
Interventions: Procedure: repetitive Transcranial Magnetic Stimulation (rTMS);   Behavioral: counseling
Outcome Measures: Time for relapse;   Hamilton Depression Rating Scale;   Illness severity change;   subject functioning
19 Recruiting Prolonging Remission in Depressed Elderly (PRIDE)
Condition: Depression
Interventions: Drug: lithium and Venlafaxine;   Procedure: ECT
Outcome Measures: Long-term antidepressant efficacy (Hamilton Rating Scale for Depression);   Level of functioning (SF-36);   Tolerability (Mini Mental State Examination [MMSE]);   Tolerability (California Verbal Learning Test [CVLT-II], Autobiographical Memory Interview-Short Form [AMI-SF]);   Tolerability (Trail Making Tests, DRS-IP and Delis-Kaplan Executive Function System, Verbal Fluency;   Safety (Udvalg for Kliniske Undersogelser [UKU] Side Effects Rating Scale)
20 Recruiting Predict Antidepressant Responsiveness Using Pharmacogenomics
Conditions: Depression;   Depressive Symptoms
Interventions: Drug: SSRI class antidepressant;   Drug: non-SSRI class antidepressant
Outcome Measure: Presences of each individual symptom of depression at 1,2,4,6,12 weeks